Full metadata record

DC Field Value Language
dc.contributor.authorLee, IH-
dc.contributor.authorPark, YT-
dc.contributor.authorRoh, K-
dc.contributor.authorChung, H-
dc.contributor.authorKwon, IC-
dc.contributor.authorJeong, SY-
dc.date.accessioned2024-01-21T05:33:49Z-
dc.date.available2024-01-21T05:33:49Z-
dc.date.created2021-09-03-
dc.date.issued2005-02-02-
dc.identifier.issn0168-3659-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/136742-
dc.description.abstractStable paclitaxel/Lipiodol solutions as well as emulsions were developed for the treatment of solid tumors including hepatocellular carcinoma. Paclitaxel could be dissolved in Lipiodol, an oily contrast medium, but precipitated out and formed aggregates with time. Paclitaxel precipitation was due to the inter- and intra-molecular hydrogen bonding of paclitaxel molecules. Time-dependent paclitaxel aggregation was completely prevented by adding small amounts of additional solvents, which are miscible with Lipiodol. It was also notable that paclitaxel helped in stabilizing the water-in-oil (w/o) type emulsion of Lipiodol and lopamiro. The stability, physical properties and in vitro drug release profiles of the stable paclitaxel solutions and emulsions were characterized. When the stable oily paclitaxel solution was used for the treatment of B16F10 melanoma in C57BL/6 mice, the malignant cells were eradicated completely in 2 weeks, whereas the solid tumor grew rapidly and metastasized to the thigh and to other organs in the control group. Also, the mice survived for more than 1 year after the paclitaxel treatment, whereas all of those in the control group died in 40 days. (C) 2004 Elsevier B.V. All rights reserved.-
dc.languageEnglish-
dc.publisherELSEVIER SCIENCE BV-
dc.subjectTRANSCATHETER ARTERIAL CHEMOEMBOLIZATION-
dc.subjectANTITUMOR AGENTS-
dc.subjectANTICANCER AGENT-
dc.subjectHEPATOMA-
dc.subjectTAXOL-
dc.subjectLIPIODOL-
dc.subjectDELIVERY-
dc.subjectCANCER-
dc.subjectMICROSPHERES-
dc.subjectMETASTASES-
dc.titleStable paclitaxel formulations in oily contrast medium-
dc.typeArticle-
dc.identifier.doi10.1016/j.jconrel.2004.10.023-
dc.description.journalClass1-
dc.identifier.bibliographicCitationJOURNAL OF CONTROLLED RELEASE, v.102, no.2, pp.415 - 425-
dc.citation.titleJOURNAL OF CONTROLLED RELEASE-
dc.citation.volume102-
dc.citation.number2-
dc.citation.startPage415-
dc.citation.endPage425-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.identifier.wosid000226628100008-
dc.identifier.scopusid2-s2.0-11844255661-
dc.relation.journalWebOfScienceCategoryChemistry, Multidisciplinary-
dc.relation.journalWebOfScienceCategoryPharmacology & Pharmacy-
dc.relation.journalResearchAreaChemistry-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.type.docTypeArticle-
dc.subject.keywordPlusTRANSCATHETER ARTERIAL CHEMOEMBOLIZATION-
dc.subject.keywordPlusANTITUMOR AGENTS-
dc.subject.keywordPlusANTICANCER AGENT-
dc.subject.keywordPlusHEPATOMA-
dc.subject.keywordPlusTAXOL-
dc.subject.keywordPlusLIPIODOL-
dc.subject.keywordPlusDELIVERY-
dc.subject.keywordPlusCANCER-
dc.subject.keywordPlusMICROSPHERES-
dc.subject.keywordPlusMETASTASES-
dc.subject.keywordAuthorpaclitaxel-
dc.subject.keywordAuthorlipiodol-
dc.subject.keywordAuthoroily contrast medium-
dc.subject.keywordAuthoremulsion-
dc.subject.keywordAuthorcancer-
Appears in Collections:
KIST Article > 2005
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE